Skip to main content
Erschienen in: Clinical Autonomic Research 1/2020

02.09.2019 | Research Article

Human papillomavirus (HPV) vaccine and autonomic disorders: a position statement from the American Autonomic Society

verfasst von: Alexandru Barboi, Christopher H. Gibbons, Felicia Axelrod, Eduardo E. Benarroch, Italo Biaggioni, Mark W. Chapleau, Gisela Chelimsky, Thomas Chelimsky, William P. Cheshire, Victoria E. Claydon, Roy Freeman, David S. Goldstein, Michael J. Joyner, Horacio Kaufmann, Phillip A. Low, Lucy Norcliffe-Kaufmann, David Robertson, Cyndya A. Shibao, Wolfgang Singer, Howard Snapper, Steven Vernino, Satish R. Raj, on behalf of the American Autonomic Society

Erschienen in: Clinical Autonomic Research | Ausgabe 1/2020

Einloggen, um Zugang zu erhalten

Abstract

Introduction

Human papillomavirus (HPV) vaccination has been anecdotally connected to the development of dysautonomia, chronic fatigue, complex regional pain syndrome and postural tachycardia syndrome.

Objectives

To critically evaluate a potential connection between HPV vaccination and the above-noted conditions.

Methods

We reviewed the literature containing the biology of the virus, pathophysiology of infection, epidemiology of associated cancers, indications of HPV vaccination, safety surveillance data and published reports linking HPV vaccination to autonomic disorders.

Results

At this time, the American Autonomic Society finds that there are no data to support a causal relationship between HPV vaccination and CRPS, chronic fatigue, and postural tachycardia syndrome to other forms of dysautonomia.

Conclusion

Certain conditions are prevalent in the same populations that are vaccinated with the HPV vaccine (peri-pubertal males and females). This association, however, is an insufficient proof of causality.
Literatur
1.
Zurück zum Zitat Hamborsky J, Kroger A, Wolfe S (2015) Human papillomavirus. In: Hamborsky J, Kroger A, Wolfe S (eds) Centers for Disease Control and Prevention. Epidemiology and prevention of vaccine preventable diseases, 13 edn. Public Health Foundation, Washington, pp 175–185 Hamborsky J, Kroger A, Wolfe S (2015) Human papillomavirus. In: Hamborsky J, Kroger A, Wolfe S (eds) Centers for Disease Control and Prevention. Epidemiology and prevention of vaccine preventable diseases, 13 edn. Public Health Foundation, Washington, pp 175–185
2.
Zurück zum Zitat O’Leary ST, Campbell JD, Kimberlin DW (2018) Update from the advisory committee on immunization practices. J Pediatric Infect Dis Soc 7(4):270–274PubMedCrossRef O’Leary ST, Campbell JD, Kimberlin DW (2018) Update from the advisory committee on immunization practices. J Pediatric Infect Dis Soc 7(4):270–274PubMedCrossRef
3.
Zurück zum Zitat Doorbar J, Egawa N, Griffin H, Kranjec C, Murakami I (2015) Human papillomavirus molecular biology and disease association. Rev Med Virol 25(Suppl 1):2–23PubMedPubMedCentralCrossRef Doorbar J, Egawa N, Griffin H, Kranjec C, Murakami I (2015) Human papillomavirus molecular biology and disease association. Rev Med Virol 25(Suppl 1):2–23PubMedPubMedCentralCrossRef
4.
Zurück zum Zitat Bruni L, Diaz M, Castellsagué X, Ferrer E, Bosch FX, de Sanjosé S (2010) Cervical human papillomavirus prevalence in five continents: meta-analysis of 1 million women with normal cytological findings. J Infect Dis 202(12):1789–1799PubMedCrossRef Bruni L, Diaz M, Castellsagué X, Ferrer E, Bosch FX, de Sanjosé S (2010) Cervical human papillomavirus prevalence in five continents: meta-analysis of 1 million women with normal cytological findings. J Infect Dis 202(12):1789–1799PubMedCrossRef
5.
Zurück zum Zitat Doorbar J (2016) Model systems of human papillomavirus-associated disease. J Pathol 238(2):166–179PubMedCrossRef Doorbar J (2016) Model systems of human papillomavirus-associated disease. J Pathol 238(2):166–179PubMedCrossRef
6.
Zurück zum Zitat Doorbar J (2018) Host control of human papillomavirus infection and disease. Best Pract Res Clin Obstet Gynaecol 47:27–41PubMedCrossRef Doorbar J (2018) Host control of human papillomavirus infection and disease. Best Pract Res Clin Obstet Gynaecol 47:27–41PubMedCrossRef
7.
Zurück zum Zitat Schiffman M, Castle PE, Jeronimo J, Rodriguez AC, Wacholder S (2007) Human papillomavirus and cervical cancer. Lancet 370(9590):890–907PubMedCrossRef Schiffman M, Castle PE, Jeronimo J, Rodriguez AC, Wacholder S (2007) Human papillomavirus and cervical cancer. Lancet 370(9590):890–907PubMedCrossRef
8.
Zurück zum Zitat Bosch FX, Broker TR, Forman D et al (2013) Comprehensive control of human papillomavirus infections and related diseases. Vaccine 31(Suppl 7):H1–H31PubMedCrossRefPubMedCentral Bosch FX, Broker TR, Forman D et al (2013) Comprehensive control of human papillomavirus infections and related diseases. Vaccine 31(Suppl 7):H1–H31PubMedCrossRefPubMedCentral
9.
Zurück zum Zitat Forman D, de Martel C, Lacey CJ et al (2012) Global burden of human papillomavirus and related diseases. Vaccine 30(Suppl 5):F12–F23PubMedCrossRef Forman D, de Martel C, Lacey CJ et al (2012) Global burden of human papillomavirus and related diseases. Vaccine 30(Suppl 5):F12–F23PubMedCrossRef
10.
Zurück zum Zitat Khode SR, Dwivedi RC, Rhys-Evans P, Kazi R (2014) Exploring the link between human papilloma virus and oral and oropharyngeal cancers. J Cancer Res Ther 10(3):492–498PubMed Khode SR, Dwivedi RC, Rhys-Evans P, Kazi R (2014) Exploring the link between human papilloma virus and oral and oropharyngeal cancers. J Cancer Res Ther 10(3):492–498PubMed
11.
Zurück zum Zitat Bryan JT, Buckland B, Hammond J, Jansen KU (2016) Prevention of cervical cancer: journey to develop the first human papillomavirus virus-like particle vaccine and the next generation vaccine. Curr Opin Chem Biol 32:34–47PubMedCrossRef Bryan JT, Buckland B, Hammond J, Jansen KU (2016) Prevention of cervical cancer: journey to develop the first human papillomavirus virus-like particle vaccine and the next generation vaccine. Curr Opin Chem Biol 32:34–47PubMedCrossRef
12.
Zurück zum Zitat World Health Organization (2017) Human papillomavirus vaccines: WHO position paper, May 2017-recommendations. Vaccine 35(43):5753–5755CrossRef World Health Organization (2017) Human papillomavirus vaccines: WHO position paper, May 2017-recommendations. Vaccine 35(43):5753–5755CrossRef
13.
Zurück zum Zitat Markowitz LE, Dunne EF, Saraiya M et al (2007) Quadrivalent human papillomavirus vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 56(RR-2):1–24PubMed Markowitz LE, Dunne EF, Saraiya M et al (2007) Quadrivalent human papillomavirus vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 56(RR-2):1–24PubMed
14.
Zurück zum Zitat Centers for Disease Control and Prevention (2010) FDA licensure of quadrivalent human papillomavirus vaccine (HPV4, Gardasil) for use in males and guidance from the advisory committee on immunization practices (ACIP). MMWR Morb Mortal Wkly Rep 59(20):630–632 Centers for Disease Control and Prevention (2010) FDA licensure of quadrivalent human papillomavirus vaccine (HPV4, Gardasil) for use in males and guidance from the advisory committee on immunization practices (ACIP). MMWR Morb Mortal Wkly Rep 59(20):630–632
15.
Zurück zum Zitat Centers for Disease Control and Prevention (2010) FDA licensure of bivalent human papillomavirus vaccine (HPV2, Cervarix) for use in females and updated HPV vaccination recommendations from the advisory committee on immunization practices (ACIP). MMWR Morb Mortal Wkly Rep 59(20):626–629 Centers for Disease Control and Prevention (2010) FDA licensure of bivalent human papillomavirus vaccine (HPV2, Cervarix) for use in females and updated HPV vaccination recommendations from the advisory committee on immunization practices (ACIP). MMWR Morb Mortal Wkly Rep 59(20):626–629
16.
Zurück zum Zitat Dalianis T (2014) Human papillomavirus and oropharyngeal cancer, the epidemics, and significance of additional clinical biomarkers for prediction of response to therapy (Review). Int J Oncol 44(6):1799–1805PubMedPubMedCentralCrossRef Dalianis T (2014) Human papillomavirus and oropharyngeal cancer, the epidemics, and significance of additional clinical biomarkers for prediction of response to therapy (Review). Int J Oncol 44(6):1799–1805PubMedPubMedCentralCrossRef
17.
Zurück zum Zitat Jain KS, Sikora AG, Baxi SS, Morris LG (2013) Synchronous cancers in patients with head and neck cancer: risks in the era of human papillomavirus-associated oropharyngeal cancer. Cancer 119(10):1832–1837PubMedCrossRef Jain KS, Sikora AG, Baxi SS, Morris LG (2013) Synchronous cancers in patients with head and neck cancer: risks in the era of human papillomavirus-associated oropharyngeal cancer. Cancer 119(10):1832–1837PubMedCrossRef
18.
Zurück zum Zitat Jelihovschi I, Bidescu AC, Tucaliuc SE, Iancu LS (2015) Detection of human papilloma virus in head and neck squamous cell carcinomas: a literature review. Rev Med Chir Soc Med Nat Iasi 119(2):502–509PubMed Jelihovschi I, Bidescu AC, Tucaliuc SE, Iancu LS (2015) Detection of human papilloma virus in head and neck squamous cell carcinomas: a literature review. Rev Med Chir Soc Med Nat Iasi 119(2):502–509PubMed
19.
Zurück zum Zitat Angioli R, Lopez S, Aloisi A et al (2016) Ten years of HPV vaccines: state of art and controversies. Crit Rev Oncol Hematol 102:65–72PubMedCrossRef Angioli R, Lopez S, Aloisi A et al (2016) Ten years of HPV vaccines: state of art and controversies. Crit Rev Oncol Hematol 102:65–72PubMedCrossRef
20.
Zurück zum Zitat Schiller JT, Castellsagué X, Garland SM (2012) A review of clinical trials of human papillomavirus prophylactic vaccines. Vaccine 30(Suppl 5):F123–F138PubMedPubMedCentralCrossRef Schiller JT, Castellsagué X, Garland SM (2012) A review of clinical trials of human papillomavirus prophylactic vaccines. Vaccine 30(Suppl 5):F123–F138PubMedPubMedCentralCrossRef
21.
Zurück zum Zitat Maver PJ, Poljak M (2018) Progress in prophylactic human papillomavirus (HPV) vaccination in 2016: a literature review. Vaccine 36(36):5416–5423PubMedCrossRef Maver PJ, Poljak M (2018) Progress in prophylactic human papillomavirus (HPV) vaccination in 2016: a literature review. Vaccine 36(36):5416–5423PubMedCrossRef
22.
Zurück zum Zitat Ackerson B, Hechter R, Sidell M et al (2017) Human papillomavirus vaccine series completion in boys before and after recommendation for routine immunization. Vaccine 35(6):897–902PubMedCrossRef Ackerson B, Hechter R, Sidell M et al (2017) Human papillomavirus vaccine series completion in boys before and after recommendation for routine immunization. Vaccine 35(6):897–902PubMedCrossRef
23.
Zurück zum Zitat Gee J, Weinbaum C, Sukumaran L, Markowitz LE (2016) Quadrivalent HPV vaccine safety review and safety monitoring plans for nine-valent HPV vaccine in the United States. Hum Vaccin Immunother 12(6):1406–1417PubMedPubMedCentralCrossRef Gee J, Weinbaum C, Sukumaran L, Markowitz LE (2016) Quadrivalent HPV vaccine safety review and safety monitoring plans for nine-valent HPV vaccine in the United States. Hum Vaccin Immunother 12(6):1406–1417PubMedPubMedCentralCrossRef
24.
Zurück zum Zitat Hillman RJ, Giuliano AR, Palefsky JM et al (2012) Immunogenicity of the quadrivalent human papillomavirus (type 6/11/16/18) vaccine in males 16 to 26 years old. Clin Vaccine Immunol 19(2):261–267PubMedPubMedCentralCrossRef Hillman RJ, Giuliano AR, Palefsky JM et al (2012) Immunogenicity of the quadrivalent human papillomavirus (type 6/11/16/18) vaccine in males 16 to 26 years old. Clin Vaccine Immunol 19(2):261–267PubMedPubMedCentralCrossRef
25.
Zurück zum Zitat Macartney KK, Chiu C, Georgousakis M, Brotherton JM (2013) Safety of human papillomavirus vaccines: a review. Drug Saf 36(6):393–412PubMedCrossRef Macartney KK, Chiu C, Georgousakis M, Brotherton JM (2013) Safety of human papillomavirus vaccines: a review. Drug Saf 36(6):393–412PubMedCrossRef
26.
Zurück zum Zitat Phillips A, Patel C, Pillsbury A, Brotherton J, Macartney K (2018) Safety of human papillomavirus vaccines: an updated review. Drug Saf 41(4):329–346PubMedCrossRef Phillips A, Patel C, Pillsbury A, Brotherton J, Macartney K (2018) Safety of human papillomavirus vaccines: an updated review. Drug Saf 41(4):329–346PubMedCrossRef
27.
Zurück zum Zitat van Klooster TM, Kemmeren JM, van der Maas NA, de Melker HE (2011) Reported adverse events in girls aged 13-16 years after vaccination with the human papillomavirus (HPV)-16/18 vaccine in the Netherlands. Vaccine 29(28):4601–4607PubMedCrossRef van Klooster TM, Kemmeren JM, van der Maas NA, de Melker HE (2011) Reported adverse events in girls aged 13-16 years after vaccination with the human papillomavirus (HPV)-16/18 vaccine in the Netherlands. Vaccine 29(28):4601–4607PubMedCrossRef
28.
Zurück zum Zitat Rambout L, Hopkins L, Hutton B, Fergusson D (2007) Prophylactic vaccination against human papillomavirus infection and disease in women: a systematic review of randomized controlled trials. CMAJ 177(5):469–479PubMedPubMedCentralCrossRef Rambout L, Hopkins L, Hutton B, Fergusson D (2007) Prophylactic vaccination against human papillomavirus infection and disease in women: a systematic review of randomized controlled trials. CMAJ 177(5):469–479PubMedPubMedCentralCrossRef
29.
Zurück zum Zitat Skufca J, Ollgren J, Artama M, Ruokokoski E, Nohynek H, Palmu AA (2018) The association of adverse events with bivalent human papilloma virus vaccination: a nationwide register-based cohort study in Finland. Vaccine 36(39):5926–5933PubMedCrossRef Skufca J, Ollgren J, Artama M, Ruokokoski E, Nohynek H, Palmu AA (2018) The association of adverse events with bivalent human papilloma virus vaccination: a nationwide register-based cohort study in Finland. Vaccine 36(39):5926–5933PubMedCrossRef
30.
Zurück zum Zitat GAVS (2017) Meeting of the Global Advisory Committee on Vaccine Safety, 7–8 June 2017. Wkly Epidemiol Rec 92(28):393–402 GAVS (2017) Meeting of the Global Advisory Committee on Vaccine Safety, 7–8 June 2017. Wkly Epidemiol Rec 92(28):393–402
31.
Zurück zum Zitat Arana J, Mba-Jonas A, Jankosky C et al (2017) Reports of postural orthostatic tachycardia syndrome after human papillomavirus vaccination in the vaccine adverse event reporting system. J Adolesc Health 61(5):577–582PubMedCrossRef Arana J, Mba-Jonas A, Jankosky C et al (2017) Reports of postural orthostatic tachycardia syndrome after human papillomavirus vaccination in the vaccine adverse event reporting system. J Adolesc Health 61(5):577–582PubMedCrossRef
32.
Zurück zum Zitat Skufca J, Ollgren J, Ruokokoski E, Lyytikäinen O, Nohynek H (2017) Incidence rates of Guillain Barré (GBS), chronic fatigue/systemic exertion intolerance disease (CFS/SEID) and postural orthostatic tachycardia syndrome (POTS) prior to introduction of human papilloma virus (HPV) vaccination among adolescent girls in Finland, 2002–2012. Papillomavirus Res 3:91–96PubMedPubMedCentralCrossRef Skufca J, Ollgren J, Ruokokoski E, Lyytikäinen O, Nohynek H (2017) Incidence rates of Guillain Barré (GBS), chronic fatigue/systemic exertion intolerance disease (CFS/SEID) and postural orthostatic tachycardia syndrome (POTS) prior to introduction of human papilloma virus (HPV) vaccination among adolescent girls in Finland, 2002–2012. Papillomavirus Res 3:91–96PubMedPubMedCentralCrossRef
33.
Zurück zum Zitat Blitshteyn S (2014) Postural tachycardia syndrome following human papillomavirus vaccination. Eur J Neurol 21(1):135–139PubMedCrossRef Blitshteyn S (2014) Postural tachycardia syndrome following human papillomavirus vaccination. Eur J Neurol 21(1):135–139PubMedCrossRef
34.
Zurück zum Zitat Brinth LS, Pors K, Theibel AC, Mehlsen J (2015) Orthostatic intolerance and postural tachycardia syndrome as suspected adverse effects of vaccination against human papilloma virus. Vaccine 33(22):2602–2605PubMedCrossRef Brinth LS, Pors K, Theibel AC, Mehlsen J (2015) Orthostatic intolerance and postural tachycardia syndrome as suspected adverse effects of vaccination against human papilloma virus. Vaccine 33(22):2602–2605PubMedCrossRef
35.
36.
Zurück zum Zitat Martínez-Lavín M (2015) Hypothesis: human papillomavirus vaccination syndrome–small fiber neuropathy and dysautonomia could be its underlying pathogenesis. Clin Rheumatol 34(7):1165–1169PubMedCrossRef Martínez-Lavín M (2015) Hypothesis: human papillomavirus vaccination syndrome–small fiber neuropathy and dysautonomia could be its underlying pathogenesis. Clin Rheumatol 34(7):1165–1169PubMedCrossRef
37.
Zurück zum Zitat Hendrickson JE, Hendrickson ET, Gehrie EA et al (2016) Complex regional pain syndrome and dysautonomia in a 14-year-old girl responsive to therapeutic plasma exchange. J Clin Apher 31(4):368–374PubMedCrossRef Hendrickson JE, Hendrickson ET, Gehrie EA et al (2016) Complex regional pain syndrome and dysautonomia in a 14-year-old girl responsive to therapeutic plasma exchange. J Clin Apher 31(4):368–374PubMedCrossRef
38.
Zurück zum Zitat Takahashi Y, Matsudaira T, Nakano H et al (2016) Immunological studies of cerebrospinal fluid from patients with CNS symptoms after human papillomavirus vaccination. J Neuroimmunol 298:71–78PubMedCrossRef Takahashi Y, Matsudaira T, Nakano H et al (2016) Immunological studies of cerebrospinal fluid from patients with CNS symptoms after human papillomavirus vaccination. J Neuroimmunol 298:71–78PubMedCrossRef
39.
Zurück zum Zitat Baker B, Eça Guimarães L, Tomljenovic L, Agmon-Levin N, Shoenfeld Y (2015) The safety of human papilloma virus-blockers and the risk of triggering autoimmune diseases. Expert Opin Drug Saf 14(9):1387–1394PubMedCrossRef Baker B, Eça Guimarães L, Tomljenovic L, Agmon-Levin N, Shoenfeld Y (2015) The safety of human papilloma virus-blockers and the risk of triggering autoimmune diseases. Expert Opin Drug Saf 14(9):1387–1394PubMedCrossRef
40.
Zurück zum Zitat Tomljenovic L, Colafrancesco S, Perricone C, Shoenfeld Y (2014) Postural orthostatic tachycardia with chronic fatigue after HPV vaccination as part of the “autoimmune/auto-inflammatory syndrome induced by adjuvants”: case report and literature review. J Investig Med High Impact Case Rep 2(1):2324709614527812PubMedPubMedCentral Tomljenovic L, Colafrancesco S, Perricone C, Shoenfeld Y (2014) Postural orthostatic tachycardia with chronic fatigue after HPV vaccination as part of the “autoimmune/auto-inflammatory syndrome induced by adjuvants”: case report and literature review. J Investig Med High Impact Case Rep 2(1):2324709614527812PubMedPubMedCentral
41.
Zurück zum Zitat Freeman R, Wieling W, Axelrod FB et al (2011) Consensus statement on the definition of orthostatic hypotension, neurally mediated syncope and the postural tachycardia syndrome. Clin Auton Res 21(2):69–72PubMedCrossRef Freeman R, Wieling W, Axelrod FB et al (2011) Consensus statement on the definition of orthostatic hypotension, neurally mediated syncope and the postural tachycardia syndrome. Clin Auton Res 21(2):69–72PubMedCrossRef
42.
Zurück zum Zitat Butts BN, Fischer PR, Mack KJ (2017) Human papillomavirus vaccine and postural orthostatic tachycardia syndrome: a review of current literature. J Child Neurol 32(11):956–965PubMedCrossRef Butts BN, Fischer PR, Mack KJ (2017) Human papillomavirus vaccine and postural orthostatic tachycardia syndrome: a review of current literature. J Child Neurol 32(11):956–965PubMedCrossRef
44.
Zurück zum Zitat Iwata S, Okada K, Kawana K, Expert Council on Promotion of Vaccination (2017) Consensus statement from 17 relevant Japanese academic societies on the promotion of the human papillomavirus vaccine. Vaccine 35(18):2291–2292PubMedCrossRef Iwata S, Okada K, Kawana K, Expert Council on Promotion of Vaccination (2017) Consensus statement from 17 relevant Japanese academic societies on the promotion of the human papillomavirus vaccine. Vaccine 35(18):2291–2292PubMedCrossRef
45.
Zurück zum Zitat Dixon GN (2017) Making vaccine messaging stick: perceived causal instability as a barrier to effective vaccine messaging. J Health Commun 22(8):631–637PubMedCrossRef Dixon GN (2017) Making vaccine messaging stick: perceived causal instability as a barrier to effective vaccine messaging. J Health Commun 22(8):631–637PubMedCrossRef
46.
Zurück zum Zitat Mølbak K, Hansen ND, Valentiner-Branth P (2016) Pre-vaccination care-seeking in females reporting severe adverse reactions to HPV vaccine A registry based case-control study. PLoS One 11(9):e0162520PubMedPubMedCentralCrossRef Mølbak K, Hansen ND, Valentiner-Branth P (2016) Pre-vaccination care-seeking in females reporting severe adverse reactions to HPV vaccine A registry based case-control study. PLoS One 11(9):e0162520PubMedPubMedCentralCrossRef
48.
Zurück zum Zitat Tafuri S, Fortunato F, Gallone MS et al (2018) Systematic causality assessment of adverse events following HPV vaccines: analysis of current data from Apulia region (Italy). Vaccine 36(8):1072–1077PubMedCrossRef Tafuri S, Fortunato F, Gallone MS et al (2018) Systematic causality assessment of adverse events following HPV vaccines: analysis of current data from Apulia region (Italy). Vaccine 36(8):1072–1077PubMedCrossRef
49.
Zurück zum Zitat Works Health Organization (2018) Causality assessment of an adverse event following immunization (AEFI): user manual for the revised WHO classification. WHO, Geneva. Accessed Dec 2018 Works Health Organization (2018) Causality assessment of an adverse event following immunization (AEFI): user manual for the revised WHO classification. WHO, Geneva. Accessed Dec 2018
50.
Zurück zum Zitat Drolet M, Bénard É, Boily MC et al (2015) Population-level impact and herd effects following human papillomavirus vaccination programmes: a systematic review and meta-analysis. Lancet Infect Dis 15(5):565–580PubMedPubMedCentralCrossRef Drolet M, Bénard É, Boily MC et al (2015) Population-level impact and herd effects following human papillomavirus vaccination programmes: a systematic review and meta-analysis. Lancet Infect Dis 15(5):565–580PubMedPubMedCentralCrossRef
51.
Zurück zum Zitat Cameron RL, Ahmed S, Pollock KG (2016) Adverse event monitoring of the human papillomavirus vaccines in Scotland. Intern Med J 46(4):452–457PubMedCrossRef Cameron RL, Ahmed S, Pollock KG (2016) Adverse event monitoring of the human papillomavirus vaccines in Scotland. Intern Med J 46(4):452–457PubMedCrossRef
52.
Zurück zum Zitat Petousis-Harris H (2016) Proposed HPV vaccination syndrome is unsubstantiated. Clin Rheumatol 35(3):833–834PubMedCrossRef Petousis-Harris H (2016) Proposed HPV vaccination syndrome is unsubstantiated. Clin Rheumatol 35(3):833–834PubMedCrossRef
53.
Zurück zum Zitat Andrews N, Stowe J, Miller E (2017) No increased risk of Guillain-Barré syndrome after human papilloma virus vaccine: a self-controlled case-series study in England. Vaccine 35(13):1729–1732PubMedCrossRef Andrews N, Stowe J, Miller E (2017) No increased risk of Guillain-Barré syndrome after human papilloma virus vaccine: a self-controlled case-series study in England. Vaccine 35(13):1729–1732PubMedCrossRef
54.
Zurück zum Zitat Donegan K, Beau-Lejdstrom R, King B, Seabroke S, Thomson A, Bryan P (2013) Bivalent human papillomavirus vaccine and the risk of fatigue syndromes in girls in the UK. Vaccine 31(43):4961–4967PubMedCrossRef Donegan K, Beau-Lejdstrom R, King B, Seabroke S, Thomson A, Bryan P (2013) Bivalent human papillomavirus vaccine and the risk of fatigue syndromes in girls in the UK. Vaccine 31(43):4961–4967PubMedCrossRef
55.
Zurück zum Zitat Miranda S, Chaignot C, Collin C, Dray-Spira R, Weill A, Zureik M (2017) Human papillomavirus vaccination and risk of autoimmune diseases: a large cohort study of over 2 million young girls in France. Vaccine 35(36):4761–4768PubMedCrossRef Miranda S, Chaignot C, Collin C, Dray-Spira R, Weill A, Zureik M (2017) Human papillomavirus vaccination and risk of autoimmune diseases: a large cohort study of over 2 million young girls in France. Vaccine 35(36):4761–4768PubMedCrossRef
56.
Zurück zum Zitat Grimaldi-Bensouda L, Rossignol M, Koné-Paut I et al (2017) Risk of autoimmune diseases and human papilloma virus (HPV) vaccines: six years of case-referent surveillance. J Autoimmun 79:84–90PubMedCrossRef Grimaldi-Bensouda L, Rossignol M, Koné-Paut I et al (2017) Risk of autoimmune diseases and human papilloma virus (HPV) vaccines: six years of case-referent surveillance. J Autoimmun 79:84–90PubMedCrossRef
57.
Zurück zum Zitat Liu EY, Smith LM, Ellis AK et al (2018) Quadrivalent human papillomavirus vaccination in girls and the risk of autoimmune disorders: the Ontario Grade 8 HPV vaccine cohort study. CMAJ 190(21):E648–E655PubMedPubMedCentralCrossRef Liu EY, Smith LM, Ellis AK et al (2018) Quadrivalent human papillomavirus vaccination in girls and the risk of autoimmune disorders: the Ontario Grade 8 HPV vaccine cohort study. CMAJ 190(21):E648–E655PubMedPubMedCentralCrossRef
Metadaten
Titel
Human papillomavirus (HPV) vaccine and autonomic disorders: a position statement from the American Autonomic Society
verfasst von
Alexandru Barboi
Christopher H. Gibbons
Felicia Axelrod
Eduardo E. Benarroch
Italo Biaggioni
Mark W. Chapleau
Gisela Chelimsky
Thomas Chelimsky
William P. Cheshire
Victoria E. Claydon
Roy Freeman
David S. Goldstein
Michael J. Joyner
Horacio Kaufmann
Phillip A. Low
Lucy Norcliffe-Kaufmann
David Robertson
Cyndya A. Shibao
Wolfgang Singer
Howard Snapper
Steven Vernino
Satish R. Raj
on behalf of the American Autonomic Society
Publikationsdatum
02.09.2019
Verlag
Springer Berlin Heidelberg
Erschienen in
Clinical Autonomic Research / Ausgabe 1/2020
Print ISSN: 0959-9851
Elektronische ISSN: 1619-1560
DOI
https://doi.org/10.1007/s10286-019-00608-w

Weitere Artikel der Ausgabe 1/2020

Clinical Autonomic Research 1/2020 Zur Ausgabe